JW Pharmaceutical exports new Atopic dermatitis therapy technology to LEO Pharma
JW Pharmaceutical(CEO Jae-Kwang Jeon & Young-Sup Shin) announced on the 24th that they signed a license-out agreement of its innovative Atopic dermatitis therapy ‘JW1601’ with LEO Pharma(CEO Gitte Aabo) having specialized competitiveness in the dermatologic field.
LEO Pharma, the top dermatologi...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.